LEARNING OBJECTIVES

• Understanding the Current Epidemiology & Environment in mCRC
• Learning about new emerging treatments in mCRC, including the role of immunotherapy
• Managing toxicities and sequence agents in mCRC
• Assessing Clinical case studies in 3L mCRC

WEDNESDAY, DECEMBER 12, 2018

MUHC- GLEN
08:30 to 09:30
Block D, Room D.02.1312
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

HÔPITAL MAISONNEUVE ROSEMONT
12:00-13:00
Room TBD

NOUVEAU CHUM
17:00 to 18:00
Room D.S4.5030

THURSDAY, DECEMBER 13, 2018

JEWSH GENERAL HOSPITAL
12:30 to 13:30
Room E-711

SACRE COEUR HOSPITAL
15:00 to 16:00
Room G-4130

Refreshments will be served at each location.
To organize a videconference: vspo@mcgill.ca

This program has received an educational grant from:
AbbVie, Alexion, Agena, Apobologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Servier, Shire, Taiho Pharma, Teva Canada Innovation